(Q38078136)

28 August 2017

1 reference

title

Which drug, and when, for patients with BRAF-mutant melanoma? (English)

1 reference

28 August 2017

Sekwon Jang

1

1 reference

28 August 2017

Michael B Atkins

series ordinal

2

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Lancet Oncology Commission

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

e60-9

1 reference

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

From genes to drugs: targeted strategies for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Immunostimulatory monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Interferon-gamma priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Melanoma biology and new targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Melanoma brain metastases: is it time to reassess the bias?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

BRAF targeted therapy changes the treatment paradigm in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970539-9

7 January 2021

10.1016/S1470-2045(12)70539-9

Identifiers

DOI

1 reference

28 August 2017

1 reference